Loading…
← CockpitCompetitor Analysis › 7733.T Olympus CorporationOpen in the cockpit ↗

Olympus Corporation7733.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties

Maker of medical endoscopes and surgical devices, having exited its legacy camera business.

≈ Japan's Boston Scientific/Stryker for endoscopyMomentum neutral 52
Mkt cap
$12.7B
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$54.3M
20-day average traded
Fwd P/E
18.7×
forward earnings
ROIC−WACC
+12.7 pp
WACC 5.8%
Hurdle
-13 pp
Req g minus delivered
Next earnings
86 days
12 Feb 2027
Close · JPY¥1,798
1D+0.3%
1W+2.6%
1M+6.7%
3M-14.8%
6M+4.5%
YTD-7.6%
1Y-3.3%
ATR %3.0%
52w lowhigh18.7% off high

What Olympus does

Maker of medical endoscopes and surgical devices, having exited its legacy camera business.

Sells scopes, video processors and accessories to hospitals, with repair contracts and single-use accessories adding recurring income on top of equipment sales. It sold its camera business in 2021 to focus on medical devices.

In one line: Japan's Boston Scientific/Stryker for endoscopy.

Products and services

  • Gastrointestinal endoscopy systems
  • Surgical/energy devices
  • Urology/respiratory endoscopy

Customers

  • Hospitals/GI and surgical departments worldwide

Where it sits in the supply chain

  • Healthcare
  • Medical devices
  • Endoscopy systems, surgical energy…

What could go right

  • Growing GI cancer screening/endoscopy procedure volumes

What could go wrong

  • Past quality/regulatory compliance issues
  • Reimbursement and hospital capex cyclicality

Moat: wide (scale, installed base, regulatory licence). Global leader in GI endoscopes with a large installed base of hospital equipment and physician training.

Headquarters: Tokyo, Japan · Founded: 1919 · Employees: 28,138

Named competitors

Olympus at a glance

Size Olympus (7733.T) is a Japan Health Care company (Medical Specialties) with a market value of $12.7B, the 115th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,798 on 18 Nov 2026.

Performance Over six months the shares gained 4.5%, against +26.2% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 9.0% over the last twelve months (peer median +5.0%); the operating margin is 17.8% (peer median 15.8%).

Valuation It trades at 18.7× forward earnings against a peer median of 20.0× (9th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 12.7 points above its cost of capital (5.8% WACC).

Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 1247733.T 103
Six months, rebased to 100: Olympus against the median of its 20 peers (local-currency closes).

Olympus financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥1.07T¥1.01T¥997B¥926B¥882B
Revenue growth—+1%+8%+5%—
Gross profit¥757B¥619B¥649B¥584B¥563B
EBITDA¥311B¥214B¥255B¥215B¥243B
Net income¥91.1B¥68.2B¥118B¥243B¥143B
Free cash flow¥88.8B¥45.0B¥144B-¥4.06B¥50.9B
Capital expenditure¥78.1B¥82.4B¥65.2B¥64.6B¥70.6B
Total debt¥337B¥306B¥292B¥361B¥397B

Quarterly statements and history in the cockpit →

Olympus competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%PENSNBAXLENSKARTBIMGKOSALGNCOOAVTRDEMANTQGENBIOCOLO-BPODDBRKRRVTYGMEDZBHGH7733.T6-month return →1-month return →
Up and to the right = strong over both horizons. Olympus is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×50×100×150×PENSNBAXLENSKARTBIMGKOS688271DEMANTQGENBIOPODDBRKRGMED7733.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Olympus is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%PENSNBAXLENSKARTBIMCOOAVTRDEMANTQGENBIOCOLO-BPODDBRKRRVTYGMED7733.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Olympus is the large dot.

Olympus competitors and peer comparison

Head to head with its named competitors (7733.T vs BSX vs SYK vs 4901.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Olympus 7733.T$12.7B+5%+9%18%18.7×-6.5%
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Fujifilm 4901.T$27.9B+16%+7%10%15.8×n/a
Hoya 7741.T$49.0B-16%+13%32%27.7×14.1%

How Olympus compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Olympus against its 20 peers (data as of 18 Nov 2026)
Measure7733.TPeer medianRank in peer set
1-month return+6.7%+4.2%7th highest of 21
6-month return+4.5%+26.2%8th lowest of 21
Distance from 52-week high-18.7%-13.5%7th lowest of 21
Revenue growth (TTM)+9.0%+5.0%9th highest of 21
Operating margin17.8%15.8%7th highest of 21
Forward P/E18.7×20.0×9th cheapest of 20
Growth the price implies (Req g, 7 yrs)-6.5%11.1%least demanding of 18
Growth delivered (Del g)+6.7%+8.3%9th lowest of 18
Hurdle (Req g minus delivered)-13.2 pp+5.5 pp3rd least demanding of 18
ROIC minus cost of capital+12.7 pp-1.0 pp2nd highest of 21
EV / EBITDA7.0×14.0×cheapest of 18
Net debt / EBITDA0.5×1.8×6th least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Zimmer Biomet ZBHUnited States$19.6B+21%+7%16%11.7×7.4%+3.2%
Guardant Health GHUnited States$19.6B+26%+42%-39%n/an/an/a

Questions

Who are Olympus's main competitors?
Named competitors: Boston Scientific (BSX), Stryker (SYK), Fujifilm Medical (4901.T), Pentax Medical (Hoya) (7741.T). The cockpit's measured peer set (industry) also includes Penumbra (PEN), Smith & Nephew (SN..L), Baxter International (BAX), Lenskart Solutions (LENSKART.NS), bioMerieux (BIM.PA), Glaukos (GKOS).
Is Olympus expensive compared with its peers?
On forward p/e it trades at 18.7× against a peer median of 20.0×, 9th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Olympus stock performed?
Over six months to 18 Nov 2026 the shares returned +4.5% against +26.2% for the median peer; over one year -3.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.